The combined role of NT-proBNP and LV-GLS in the detection of early subtle chemotherapy-induced cardiotoxicity in breast cancer female patients

The Egyptian Heart Journal

Table 1 Baseline (first visit) clinical characteristics of the patients

Variables	No. (%)
Age in years, mean ± SD	47.6 ± 10.5
FH of cancer	3 (4.1)
Type of receptors
Progesterone receptor (PR) positive	48 (64.9)
Estrogen receptors (ER) positive	22 (29.8)
HER receptor positive	61 (82.5)
TNM staging^a
T (tumor size)
T1	7 (9.5)
T2	46 (62.2)
T3	21 (28.4)
N (lymph node spread)
N0	18 (24.3)
N1	56 (75.7)
M (blood spread)
M0	74 (100)
Grade of breast cancer
IDC-II^b	71 (95.9)
IDC-III^b	3 (4.1)
Site of breast cancer
Right	32 (43.2)
Left	41 (55.4)
Bilateral	1 (1.35)
Surgery
Pre chemotherapy	54 (73.0)
Post chemotherapy	20(27.1)
Planned chemotherapeutic agents
A (doxorubicin)	43 (58.1)
E (epirubicine)	27 (36.5)
T (docetaxel)	4 (5.4)
C (cyclophosphamide)	73 (98.6)

DM diabetes mellitus, HTN hypertension, IDC invasive ductal carcinoma, FH family history, T tumor, N lymph node, M metastasis
^aTNM staging where T refers to the tumor size (T1; size <2 cm, T2; size 2–5 cm, T3; size >5 cm), N refers to lymph node affection (N0; no cancer cells in the nearby lymph nodes, N1; some cancer cells are found in the axillary lymph nodes, but the nodes are not stuck to the surrounding), and M refers to blood metastases (M0; no metastases)
^bIDC, invasive ductal carcinoma (grade II is a moderately differentiated while grade III is a poorly differentiated IDC)